Quick Dispatch:
Your summit study tirzepatide Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT? orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your summit study tirzepatide Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT? ships.
Need Help?
Questions about summit study tirzepatide Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT?, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for summit study tirzepatide Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT? in your area.
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
20.29
💊 New research in obesity & heart failure The SUMMIT study looked at tirzepatide, a once-weekly injection, in people with both obesity and heart failure with preserved ejection fraction (HFpEF). Over 52
28.51
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM 🥸The SUMMIT trial
27.91
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology
29.04
In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no additional benefit over semaglutide. https://ja.ma/3JO2SQc
22.15
Other clinical trials with tirzepatide 86-88
21.85
01200-X/asset/a888810c-3ccf-4f48-b252-0dfdf720d276/main.assets/gr3_lrg.jpg "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial")
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
24.59
![Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]](https://i.ytimg.com/vi/GCCHOBLTiCk/mqdefault.jpg "Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]")
